Simple Summary This article discusses the use of peptide receptor radionuclide therapy
(PRRT) as a key treatment method for advanced, unresectable neuroendocrine tumors. It …

Simple Summary Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are the
most common neuroendocrine tumors, with the ability of overexpressing somatostatin …

Neuroendocrine neoplasms (NENs) encompass a broad spectrum of tumors throughout the
body and range in biologic behavior from indolent to aggressive. Consequently, a wide …

Background Peptide receptor radionuclide therapy (PRRT) is one of the most effective
therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors …

Given the paucity of high-certainty evidence, and differences in opinion on the use of
nuclear medicine for hematological malignancies, we embarked on a consensus process …

The clinical success of radiolabeled somatostatin analogs in the diagnosis and therapy—
“theranostics”—of tumors expressing the somatostatin subtype 2 receptor (SST2R) has …

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

Simple Summary Pheochromocytomas and paragangliomas are rare neural-crest-derived
tumors with variable prognosis. In an era of tailored treatment strategies, medical imaging …

Simple Summary Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors,
presenting in often challenging clinical scenarios, and require multidisciplinary discussion …

Background Image-based tumor dosimetry after radionuclide therapy, using the isotope
177Lu, finds application eg, for tumor-to-organ dose comparison and for dose response …